Capital World Investors lessened its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report) by 42.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,665,300 shares of the medical device company’s stock after selling 2,718,811 shares during the quarter. Capital World Investors owned 5.67% of Tandem Diabetes Care worth $129,788,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new stake in Tandem Diabetes Care in the first quarter worth about $35,000. MCF Advisors LLC increased its stake in shares of Tandem Diabetes Care by 79.3% during the first quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock valued at $36,000 after purchasing an additional 445 shares in the last quarter. Signaturefd LLC increased its stake in shares of Tandem Diabetes Care by 871.8% during the fourth quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock valued at $50,000 after purchasing an additional 1,517 shares in the last quarter. Arcadia Investment Management Corp MI increased its position in shares of Tandem Diabetes Care by 141.6% during the first quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock valued at $66,000 after acquiring an additional 1,085 shares in the last quarter. Finally, GAMMA Investing LLC bought a new stake in shares of Tandem Diabetes Care during the fourth quarter valued at approximately $73,000.
Tandem Diabetes Care Trading Down 1.5 %
Tandem Diabetes Care stock traded down $0.60 during midday trading on Friday, hitting $40.05. 4,859,906 shares of the stock were exchanged, compared to its average volume of 1,518,030. Tandem Diabetes Care, Inc. has a fifty-two week low of $13.82 and a fifty-two week high of $53.69. The stock has a market capitalization of $2.59 billion, a price-to-earnings ratio of -18.46 and a beta of 1.28. The stock’s 50-day simple moving average is $45.41 and its 200 day simple moving average is $35.83. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43.
Analyst Upgrades and Downgrades
TNDM has been the subject of a number of research analyst reports. Stifel Nicolaus lifted their target price on shares of Tandem Diabetes Care from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 22nd. Citigroup upgraded shares of Tandem Diabetes Care from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $40.00 to $57.00 in a research note on Wednesday, May 22nd. StockNews.com upgraded shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research note on Friday, April 19th. SVB Leerink upgraded shares of Tandem Diabetes Care from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $34.00 to $45.00 in a report on Thursday, April 25th. Finally, Piper Sandler reiterated an “overweight” rating and set a $50.00 price target (up from $35.00) on shares of Tandem Diabetes Care in a report on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Moderate Buy” and a consensus target price of $51.25.
View Our Latest Research Report on Tandem Diabetes Care
Insider Activity at Tandem Diabetes Care
In related news, Director Dick Allen sold 5,000 shares of Tandem Diabetes Care stock in a transaction that occurred on Thursday, May 30th. The shares were sold at an average price of $51.68, for a total value of $258,400.00. Following the completion of the transaction, the director now owns 24,396 shares in the company, valued at $1,260,785.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 2.20% of the company’s stock.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.
Featured Stories
- Five stocks we like better than Tandem Diabetes Care
- How to Evaluate a Stock Before Buying
- Why Call Options Volume for These 2 Stocks Spiked Together
- Business Services Stocks Investing
- MarketBeat Week in Review – 7/22 – 7/26
- What is the FTSE 100 index?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
Want to see what other hedge funds are holding TNDM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Free Report).
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.